Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5640_Библиотеки_им_академика_М_И_Перельмана.pdf
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 309
3.5 Improved Patient Compliance Through User-Friendly Devices
3.6 Targeted
Delivery to Specific
Lung Regions
3.7 SustainedRelease Formulations
3.8 Enhanced Absorption by Overcoming Biological Barriers
Modern inhalation devices are designed with user-friendliness in
mind and feature intuitive interfaces, simplified operations, and
clear instructions [28]. These improvements facilitate correct and
consistent device usage, leading to better adherence to prescribed
treatment regimens and improved overall therapeutic outcomes.
Novel delivery systems can be engineered to target specific regions
of the respiratory tract, such as the upper airways, bronchi, and
deep lung tissues [
29]. This targeted approach allows for more
precise treatment of localized conditions and potentially reduces
systemic exposure to the drug, thus minimizing side effects.
Innovative formulations incorporate controlled-release mechanisms that allow prolonged drug action within the respiratory system
30, 31]. This sustained-release profile can reduce dosing fre-
[
quency, improve patient convenience, and maintain therapeutic
drug levels over extended periods, potentially enhancing treatment
efficacy.
Advanced delivery systems are designed to overcome physiological
barriers in the respiratory tract, such as mucus layers and epithelial
tight junctions [
32]. By addressing these obstacles, these systems
can enhance drug absorption and bioavailability, leading to
improved therapeutic effects.
3.9 Macromolecule Delivery Facilitation
3.10 Reduced Side Effects Through Improved Targeting
3.11 Formulation Challenges Addressed
3.12 Smart Technology Integration for Personalized Treatment
Novel approaches enable the effective delivery of large molecules,
such as proteins, peptides, and nucleic acids, which have traditionally been challenging to administer via the respiratory route
33]. This capability expands the potential of inhalation therapy
[
for the treatment of a wide range of respiratory diseases and systemic conditions.
By delivering drugs more precisely to the intended site of action
within the respiratory system, these advanced systems can minimize
drug exposure to non-target tissues [
34, 35]. This targeted
approach can significantly reduce systemic side effects and improve
the overall safety profile of respiratory medications.
Some drugs pose formulation challenges because of their physicochemical properties or stability issues. Novel delivery systems offer
innovative solutions to overcome these obstacles, enabling the
development of inhalable drug formulations that were previously
unsuitable for respiratory administration [
36].
Advanced delivery systems increasingly incorporate smart technologies, such as sensors, data logging, and connectivity features.
These innovations allow for real-time monitoring of patient adherence, lung function, and treatment efficacy, enabling healthcare
310 Pabbathi Shivakumar et al.
providers to personalize and optimize treatment regimens based on
individual patient needs and responses [
37, 38].
3.13 Environmental Sustainability Considerations
Modern respirator y drug delivery systems that consider environmental considerations are being developed [
use of propellant-free devices, biodegradable materials, and designs
that minimize waste and environmental impact, aligning with
global efforts toward sustainability in healthcare.
These innovative approaches to respiratory dr ug delivery systems aim to overcome the limitations of traditional methods by
addressing key challenges in drug administration, patient compliance, and treatment efficacy. By leveraging advanced technologies
and formulation strategies, these novel systems have the potential
to revolutionize respiratory medicine and offer more effective,
convenient, and personalized treatment options for patients with
a wide ra nge of respiratory conditions. As research in this field
continues to advance, further improvements in drug delivery technologies are anticipated, leading to enhanced outcomes and quality
of life in patients with respiratory diseases.
4 Novel Drug Delivery Approaches
These novel approaches use innovative carrier systems designed to
overcome the limitations of conventional drug delivery methods
40] (Table 1).
[
39]. This includes the
4.1 NanoparticleBased Delivery
Nanoparticles, typically ranging from 1 to 100 nm in size, have
emerged as versatile drug carriers for respiratory applications. Several types of nanoparticles have been utilized, including:
1. Polymeric nanoparticles: Composed of biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA) or chitosan,
these nanoparticles offer controlled drug release and enhanced
stability [
41]. They can be engineered to target-specific cell
types or lung tissues.
2. Lipid-based nanoparticles: They include solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) and can
enhance drug solubility and cellular uptake [
42]. These proper-
ties are advantageous for the delivery of lipophilic drugs.
Inorganic nanoparticles: Materials such as gold, silver, and
silica nanoparticles can be functionalized for drug delivery and
imaging. They offer unique properties, such as surface plasmon
resonance, for theranostic applications [
3. Magnetic nanopar
ticles: These can be directed to specific lung
43].
regions using external magnetic fields, enabling targeted drug
delivery and potentially reducing systemic side effects [
44].
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 311
Table 1
Comparison of traditional vs novel respiratory drug d elivery methods
Method Key features Advantages Limitations
Typical
applications
Metered-
dose
inhalers
(MDIs)
Dry powder
inhalers
(DPIs)
Nebulizers Converts liquid medication
Pressurized canister with
propellant
Delivers precise dose of
aerosolized medication
Breath-actuated
Delivers medication as dry
powder
to fine mist
Powered by compressed air
ultrasonic waves
or
Portable and
compact
Rapid drug
delivery
Consistent
dosing
Absence of
propellants
Breath-activated,
facilitating ease
of use
Enhanced
formulation
stability
Suitable
Capable of
No
for
diverse age
groups and
conditions
delivering large
doses
specialized
breathing
technique
required
Requires
coordination of
actuation and
inhalation
Potential for
oropharyngeal
deposition
Environmental
concerns
associated with
propellants
Requires sufficient
inspiratory flow
Susceptibility to
moisture
Potential dose
variability
Limited portability
Extended
administration
time
Risk of
contamination
Asthma
COPD
Short-acting
bronchodilators
Asthma
COPD
Long-acting
bronchodilators
Inhaled
corticosteroids
asthma/
Severe
COPD
Cystic fibrosis
Delivery of
antibiotics
Nanoparticle-
based
delivery
Smart
inhalers
Utilizes engineered
nanoparticles as drug
carriers
Can be polymer, lipid, or
inorganic based
Incorporates sensors
digital technology
Tracks medication
provides feedback
and
use and
Enhanced drug
solubility and
stability
Improved cellular
uptake
Potential for
targeted
delivery
Enhances
adherence
Enables remote
monitoring
Provides data on
usage patterns
Complex
manufacturing
processes
Potential toxicity
concerns
Increased cost
Higher cost
Requires
Privacy concer
patient
technological
proficiency
ns
Gene therapy
Targeted cancer
treatments
Sustained release
formulations
Asthma/COPD
management
Clinical trials
Personalized
medicine
(continued)
312 Pabbathi Shivakumar et al.
Table 1
(continued)
Method Key features Advantages Limitations
Typical
applications
Targeted
delivery
strategies
Employs mechanisms such
as receptor-mediated or
magnetic targeting
Aims to deliver drugs to
specific lung regions
Nanoparticle-based delivery systems offer numerous advantages in drug delivery. These include enhancing drug solubility
and stability, thereby improving the bioavailability of poorly soluble
drugs. Moreover, nanoparticles facilitate enhanced cellular uptake
and intracellular delivery, enabling more efficient targeting of therapeutic agents to specific cells or tissues. The potential for sustained
drug release from nanoparticles can result in prolonged therapeutic
effects and reduced dosing frequency. Furthermore, nanoparticle
systems possess the capability to co-deliver multiple therapeutic
agents, enabling combination therapies and potentially synergistic
effects. Additionally, nanoparticles can provide protection for drugs
against degradation in the harsh lung environment, which is particularly advantageous for pulmonary drug delivery applications [45]
Fig. 2).
(
Increased local
dr
ug
concentration
Reduced systemic
side effects
Improved
therapeutic
index
Complex design
and
manufacturing
processes
Limited to specific
drug types
Increased
development
costs
Lung cancer
treatments
Localized
antibiotic
y
deliver
Treatment of focal
lung diseases
4.2 Liposomal Formulations
Liposomes are spherical vesicles composed of phospholipid bilayers
that are capable of encapsulating both hydrophilic and hydrophobic
drugs [46]. Liposomes have emerged as versatile and promising
ug delivery systems, particularly for pulmonary applications.
dr
Their capacity to encapsulate a wide range of therapeutic agents,
from small molecules to macromolecules such as proteins and
nucleic acids, renders them adaptable to various treatment modalities [47]. This versatility is further enhanced by their ability to finetune lipid composition, enabling optimized drug retention in the
lungs. By modulating factors such as lipid chain length, saturation,
and cholesterol content, researchers can design liposomes that
persist in the pulmonary environment, potentially reducing dosing
frequency and enhancing patient adherence.
The potential f
or targeted delivery represents another significant advantage of liposomal systems for pulmonary drug delivery.
Through surface modification with specific ligands or antibodies,
liposomes can be engineered to selectively bind to specific cell types
or tissues within the lungs [48]. This targeted approach not only
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 313
Fig. 2 Illustration of nanoparticle-based drug carriers interacting with lung epithelial cells
enhances therapeutic efficacy by concentrating the dr ug at the
desired site of action but also contributes to reduced systemic
toxicity. By minimizing drug exposure to healthy tissues, liposomal
formulations can potentially mitigate the adverse effects associated
with conventional drug delivery methods, thereby improving the
overall safety profile of pulmonary therapies. These combined attributes make liposomes a powerful tool for addressing the challenges
of
lung-specific drug delivery
, offering the potential for more efficacious and well-tolerated treatments for various respiratory
conditions.
4.3 P
Carriers
olymer-Based
Polymer-based carriers have emerged as versatile platforms for
respiratory drug delivery, offering distinctive properties that
enhance controlled drug release and improve bioavailability
49]. Natural polymers, such as alginate, chitosan, and hyaluronic
[
acid, exhibit biocompatibility and can form hydrogels for sustained
drug release [
50]. Synthetic polymers such as poly(lactic acid)
(PLA), poly(ε-caprolactone) (PCL), and polyethylene glycol
(PEG) provide adjustable degradation rates and customizable
release profiles [
51].
Advanced stimuli-responsive polymers react
to environmental cues, such as pH, temperature, or enzymes,
enabling targeted drug release in specific lung regions or disease
conditions. Mucoadhesive polymers, notably carbopol and chitosan
derivatives, enhance drug residence time by adhering to the airway
mucus layer [
52]. Furthermore, dendrimers and dendrigraft poly-
mers, characterized by their highly branched tree-like structures,
offer unique advantages for respiratory drug delivery, thereby
expanding the potential of polymer-based carriers in this field.
314 Pabbathi Shivakumar et al.
Dendrimers present several advantages for pulmonary drug
delivery owing to their unique structural properties. Their multifunctionality, characterized by numerous surface groups, enables
the simultaneous attachment of drugs, targeting ligands, and imaging agents, thereby facilitating versatile therapeutic approaches
53]. The controlled size and structure of dendrimers, achieved
[
through precise manipulation of dendrimer generation, allows for
tailored drug loading and release properties, thereby optimizing
delivery efficiency. Moreover, dendrimers can enhance the solubility of poorly water-soluble drugs through encapsulation or surface
complexation, thereby addressing a common challenge in drug
formulation. Certain dendrimers have demonstrated the capacity
to enhance drug transport across lung epithelial barriers, improve
transepithelial transport, and potentially increase drug bioavailabil-
54]. For example, polyamidoamine (PAMAM) dendrimers
ity [
have been shown to enhance the permeability of inhaled corticosteroids across airway epithelial cells. Additionally, cationic dendrimers can form complexes with nucleic acids, facilitating efficient
gene delivery into lung cells [
the development of dendrimer-based carriers for siRNA delivery for
the treatment of lung cancers and inflammatory lung diseases.
Exosomes and extracellular vesicles have emerged as promising
naturally occurring nanocarriers for targeted drug and gene delivery, particularly in pulmonary therapeutics [56]. These nanocarriers
offer several advantages, including reduced immunogenicity, targeted delivery capabilities, and capacity to transport diverse
cargoes. For example, exosomes derived from mesenchymal stem
cells have demonstrated efficacy in delivering anti-inflammatory
agents to mitigate pulmonary inflammation in animal models of
acute respiratory distress syndrome. Furthermore, engineered exosomes loaded with siRNA have exhibited successful gene silencing
in lung cancer cells, highlighting their potential for oncological
applications [
theranostic potential further enhances their utility in developing
innovative pulmonary therapies (Table 2).
These novel drug delivery approaches offer promising solutions
for enhancing the efficacy and safety of respiratory therapy. Ongoing research is focused on optimizing these systems for specific lung
diseases and developing combination strategies to maximize therapeutic outcomes.
55]. This property has been utilized in
57]. Their ability to traverse biological barriers and
5 Advanced Inhalation Devices
Inhalation devices have advanced significantly, revolutionizing the
delivery of respiratory medications. These improvements aim to
boost drug effectiveness, patient compliance, and treatment outcomes in various respiratory conditions. The field continues to
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 315
Table 2
Overview of different types of nanocarriers used in pulmonary drug delivery
Drugloading
Carrier type Composition Size range
Liposomes Phospholipid bilayers 50–1000 nm 5–50% Amikacin, Ciprofloxacin,
capacity
Examples of drugs
delivered
Budesonide
Polymeric
nanoparticles
Solid lipid
nanoparticles
Dendrimers Branched polymers 1–100 nm Up to 50% Doxorubicin, siRNA, DNA
Micelles Amphiphilic block
Nanoemulsions Oil, water, surfactants 20–200 nm Up to 20% Budesonide, Tacrolimus,
Carbon nanotubes Carbon cylinders 0.4–
Metal
nanoparticles
Biodegradable polymers
(e.g., PLGA, PLA)
Solid lipids, surfactants 50–1000 nm 1–30% Rifampicin, Itraconazole,
copolymers
Gold, silver, iron oxide 1–
10–1000 nm 10–30% Doxorubicin, Paclitaxel,
Insulin
Salbutamol
10–100 nm 5–25% Paclitaxel, Curcumin,
Beclomethasone
dipropionate
A
ubicin,
100 nm
in
diameter,
1–1000 nm
in length
100 nm
Cyclosporine
Up to 60% Doxorubicin, Paclitaxel,
siRNA
5–15% Cisplatin, Doxor
Photosensitizers
evolve, offering innovative solutions such as smart inhalers with
sensors and advanced particle engineering techniques for both
healthcare providers and patients.
Smart inhalers with electronic monitoring explain how these
devices can track medication use, improve adherence, and provide
data for personalized treatment.
Breath-actuated i
nhalers (
BAIs) synchronize medication release
with patient inhalation, potentially enhancing drug deposition.
These inhalers address coordination challenges and incorporate
several technical components [
58]. The inhalation-activated trigger
mechanism typically employs a spring-loaded pneumatic system,
whereas a flow sensor detects the initiation of inhalation using
pressure differential or hot-wire anemometry. A rapid-release
drug reservoir ensures prompt and precise dose delivery upon
activation, and a dose-metering system accurately measures and
dispenses the prescribed medication quantity.
The operational
principles of breath-actuated devices include
priming, inhalation detection, trigger activation, drug dispersion,
316 Pabbathi Shivakumar et al.
and resetting. Advanced features, such as variable flow rate triggering, multiple-dose reservoirs, and integrated dose counters, further
enhance their functionality. These devices adapt to diverse patient
breathing patterns, enable extended use without frequent reloading, and monitor the remaining doses to alert users when replenishment is necessary.
Soft mist inhalers (SMIs) generate slow-moving, long-lasting
aerosol clouds to improve lung deposition [
utilize liquid formulations, typically aqueous or ethanolic solutions
of the medication. A compressed spring mechanism serves as the
mechanical energy source, and a unique uniblock design with
precision-drilled nozzles forms the nozzle system. A dose-metering
chamber ensured accurate and consistent dose delivery.
The mechanism of action of soft mist inhalers involves dose
preparation, energy storage, nozzle alignment, forced impingement, and aerosol generation. These devices offer several technical
advantages, including particle size control, low-velocity aerosol
production, extended spray duration, high fine particle fraction,
and propellant-free design. Advanced features, such as dose-release
lock-out, integrated dose counters, and ergonomic design, further
enhance their usability and efficacy.
Smart inhalers incorporate electronic sensors and connectivity
features to monitor medication use and enhance patient adherence.
These devices typically comprise sensors (accelerometers, pressure
sensors, and optical sensors), microprocessors, wireless connectivity
modules, and power sources. Key features include dose counting,
inhalation analysis, time and date stamping, environmental sensors,
reminders and alerts, data encryption, and integration with electronic health records (Fig.
These advanced inhalation devices represent significant technological advancements in respiratory drug delivery and offer
enhanced precision, patient adherence, and improved therapeutic
outcomes. By addressing the various challenges associated with
traditional inhalers, these innovations aim to optimize medication
delivery and ultimately improve patient health outcomes in
respiratory care.
59]. These devices
3).
6 Targeted Drug Delivery Strategies
Targeted drug delivery strategies have emerged as a critical
approach for enhancing the efficacy and safety of therapeutic interventions, particularly in complex organ systems such as the lungs.
The following three innovative methods are aimed at improving the
specificity of drug delivery: receptor-mediated targeting,
pH-responsive drug release, and magnetic field-guided delivery.
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 317
Fig. 3 Diagram showing structure and components of a smart inhaler device
6.1 ReceptorMediated Targetin
Receptor-mediated targeting is a sophisticated approach that uti-
g
lizes specific receptors on lung cells to achieve targeted drug delivery. This method employs ligands, which are molecules designed to
bind to particular receptors, thereby facilitating drug uptake by
specific cell types [
60].
This process commences with the identification of receptors
that are overexpressed or uniquely present in target cells in the
lungs. Common targets include cell surface proteins, such as integrins, growth factor receptors, and cell adhesion molecules. Following their identification, ligands are either synthesized or selected
from existing molecules that demonstrate high affinity and specificity for these receptors.
These l
igands a
re subsequently conjugated to drug carriers,
such as nanoparticles, liposomes, or polymeric micelles. Upon
administration, these drug-ligand complexes circulate in the bloodstream until they encounter their target receptors in the lungs.
Upon binding, the complexes are internalized by cells through
receptor-mediated endocytosis, effectively delivering the drug
payload.
Receptor-mediated targeting has several advantages. This
enables increased drug concentration at the target site, reducing
systemic exposure and potential side effects [
61]. This approach
also enhances the therapeutic index of drugs by improving their
bioavailability and cellular uptake. Furthermore, it can overcome
certain biological barriers, such as the blood-air barrier in the lungs,
which often impedes conventional drug delivery methods.
318 Pabbathi Shivakumar et al.
However, challenges remain in the implementation of receptormediated targeting. These include the necessity for extensive
research to identify suitable receptor-ligand pairs, potential immunogenicity of the targeting ligands, and the complexity of
manufacturing these sophisticated drug delivery systems at scale.
6.2 pH-Responsive Drug Release
pH-responsive drug release is an intelligent drug delivery strategy
that capitalizes on pH variations within different regions of the
lungs or under specific disease conditions. This approach involves
designing drug carriers that remain stable at physiological pH but
undergo structural changes or degradation in response to alterations in the local pH, thereby releasing their drug payload.
The lungs exhibit natural pH gradients, with the airways typically having a slightly acidic pH (6.0–6.5) compared to the more
neutral pH of the alveoli (7.0–7.4). Moreover, certain pathological
conditions, such as inflammation, infection, and cancer, can further
alter the local pH. pH-responsive drug delivery systems have been
designed to exploit these differences for targeted drug release [
62].
These systems typically employ pH-sensitive polymers or lipids
that undergo conformational changes or hydrolysis in response to
specific pH conditions. Polymers with weakly acidic or basic groups
can be used for this purpose. In acidic environments, these polymers swell or dissolve, thereby releasing the encapsulated drugs.
Conversely, they remain stable in neutral or alkaline environments,
thereby preventing premature drug release.
Common pH-responsive
materials
include poly(acrylic acid)
(PAA) and its derivatives, chitosan and its derivatives, poly(histidine), and pH-sensitive lipids such as phosphatidylethanolamine.
These materials exhibit changes in their properties or behavior in
response to variations in pH, making them valuable for various
applications in fields like drug delivery, biosensors, and smart
materials.
The d
esign o
f these systems can be further refined to respond
to specific pH ranges, allowing for precise control of drug release in
different lung regions or under particular disease conditions. For
example, a drug carrier designed to release its payload at pH 6.5
could target inflamed lung tissue, whereas one that is stable at this
pH but responsive to more acidic conditions (pH < 6.0) could
target areas of severe inflammation or infection.
pH-responsive dr
ug release systems offer numerous advantages
in pharmaceutical applications. This approach enables precise spatial control of drug release, facilitating targeted delivery to specific
anatomical regions. By implementing this strategy, systemic toxicity
is mitigated through the reduction of drug exposure to healthy
tissues. Moreover, pH-responsive systems have the potential to
enhance therapeutic efficacy by releasing pharmaceutical agents in
response to disease-specific pH alterations, thereby ensuring optimal drug concentrations at the intended site of action.